Analytical Validation and Clinical Implementation of MedGenome HRD Assay: A Large Comparative Study Against Commercial HRD Assays in Ovarian Cancer

MG_HRD HRD testing in 4,163 Indian ovarian cancer FFPE samples found 52.4% HRD positivity and 23.6% pathogenic/likely pathogenic BRCA1/2 variants, with 97.1% assay agreement.

• Why it matters: Real-world HRD prevalence and assay performance data for Indian patients are limited, despite HRD being a key predictive biomarker for PARPi therapy in ovarian cancer.
• What they did: They compared commercial HRD assays (AmoyDx HRD Focus Panel, n=1,097; SOPHiA DDM HRD Solution, n=470), then developed and validated MG_HRD using 170 samples with external concordance versus Myriad myChoice CDx.
• The result: Across 2,596 routine-practice samples, BRCA wild-type tumors were HRD-positive in 28.8%, HRD scores were higher in BRCA-mutated cases (p<0.001), and MG_HRD matched commercial assays (98.3% NPA, 96.4% PPA).

AI summary of the abstract · may contain errors · not medical advice · read the paper.